Trial Profile
A Phase 1, Two-part, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of SPR206 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Aug 2021
Price :
$35
*
At a glance
- Drugs SPR-206 (Primary)
- Indications Acinetobacter infections; Gram-negative infections; Intra-abdominal infections; Urinary tract infections
- Focus Adverse reactions; First in man
- Sponsors Spero Therapeutics
- 02 Aug 2021 Results (n=94) assessing safety, tolerability, and pharmacokinetics of SPR206 in healthy subjects, published in the Antimicrobial Agents and Chemotherapy.
- 16 Mar 2020 According to an Spero Therapeutics media release, Spero expects to present final data from the Phase 1 clinical trial in the first half of 2020
- 08 Jan 2020 Status changed from recruiting to completed.